Companies Forte Biosciences, Inc.
Forte Biosciences (FBRX): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me Forte Biosciences, Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $1,450,175FY2023
- $1,674,458FY2024
- $7,358,587FY2025
CEO total pay was $7,358,587 in fiscal 2025, up from $1,674,458 in fiscal 2024.
FY2025: salary $670,051 · bonus $0 · stock awards $0 · option awards $5,951,480
Order FBRX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Executives and directors
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Paul Wagner | $670,051 | $0 | $0 | $5,951,480 | $737,056 | $0 | $0 | $7,358,587 |
| Chairman, President and Chief Executive Officer | ||||||||
| Antony Riley | 452,109 | 0 | 0 | 2,089,487 | 180,844 | 0 | 0 | 2,722,440 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Paul Wagner | $7,358,587 | $1,674,458 | $1,450,175 | ↑ +5,684,129 |
| Antony Riley | 2,722,440 | 856,875 | 722,980 | ↑ +1,865,565 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The compensation committee aims to ensure that the compensation offered to executive officers is competitive and fair by developing an appropriate group of peer companies to determine the appropriate level of overall compensation and assess each separate element of compensation.
| CEO STI target (% of salary) | NaN% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | FW Cook |
| Clawback policy | Each award under the A&R 2021 Plan will be subject to any clawback policy as may be established and/or amended from time to time to comply with applicable laws. |
| Anti-hedging | Employees, including executive officers, and Board members are prohibited from engaging in transactions that hedge or offset any decrease in the market value of equity securities granted to them or held by them. |
| Anti-pledging | Employees, including executive officers, and Board members are prohibited from pledging any of the Company's securities as collateral for any loans. |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Paul Wagner | Option | 250 | 43 | — |
| Antony Riley | RSU | 1,875 | — | 185,852 |
| Antony Riley | PSU | 2,976 | — | 294,984 |
| Paul Wagner | PSU | 3,511 | — | 294,924 |
| Paul Wagner | RSU | 6,250 | — | 525,000 |
| Antony Riley | Option | 7,875 | 17.25 | — |
| Paul Wagner | Option | 24,750 | 17.25 | — |
| Antony Riley | Option | 224,306 | 7.54 | — |
| Paul Wagner | Option | 638,889 | 7.54 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Barbara K. Finck, M.DNot independent | $0 | $0 | $186,719 | — | $600,000 | $786,719 |
| Steven KornfeldIndependent · Audit · Nominating and Corporate Governance (Chair) · Compensation | 87,614 | 0 | 200,539 | — | 0 | 288,153 |
| Richard VincentIndependent · Audit (Chair) | 71,202 | 0 | 200,539 | — | 0 | 271,741 |
| Scott Brun, M.DIndependent | 54,480 | 0 | 200,539 | — | 0 | 255,019 |
| David GryskaIndependent · Audit | 52,067 | 0 | 200,539 | — | 0 | 252,606 |
| Stephen K. Doberstein, Ph.DIndependent · Compensation | 49,480 | 0 | 200,539 | — | 0 | 250,019 |
| Shiv KapoorIndependent · Compensation | 47,500 | 0 | 200,539 | — | 0 | 248,039 |
| Paul A. Wagner, Ph.DEmployee director · Board Chair | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $42,500 |
|---|---|
| Annual equity retainer | $350,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 14,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $362,343 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $600,000 |
| Total cost of the board | $962,343 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Forte Biosciences as a peer
Companies that benchmark against FBRX
No companies currently name FBRX as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Forte Biosciences, Inc. | 2025 | Paul Wagner | $670,051 | $0 | $5,951,480 | $737,056 | $7,358,587 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-29 | 12,143,153 | 3,764,729 | 352,089 | 76.33% | Passed |
| 2023 | 2023-09-19 | 9,907,983 | 11,751,111 | 5,835,028 | 45.75% | Failed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-29 | 76.33%a |
| 2023 | 2023-09-19 | 45.75%b |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (15 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Paul Wagner. DEF 14A, filed 2026-04-29. Section “Executive Compensation”. As printed: 7,358,587. View filing ↗
- Section 01, Antony Riley. DEF 14A, filed 2026-04-29. Section “Executive Compensation”. As printed: 2,722,440. View filing ↗
- Section 08, Barbara K. Finck, M.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 786,719. View filing ↗
- Section 08, Steven Kornfeld. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 288,153. View filing ↗
- Section 08, Richard Vincent. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 271,741. View filing ↗
- Section 08, Scott Brun, M.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 255,019. View filing ↗
- Section 08, David Gryska. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 252,606. View filing ↗
- Section 08, Stephen K. Doberstein, Ph.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 250,019. View filing ↗
- Section 08, Shiv Kapoor. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 248,039. View filing ↗
- Section 08, Paul A. Wagner, Ph.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-02. Item 5.07 · say-on-pay result. As reported: 76.33% (votes for as printed: 12,143,153). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-09-20. Item 5.07 · say-on-pay result. As reported: 45.75% (votes for as printed: 9,907,983). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 362,343 + equity 0 + all other 600,000 = 962,343, summed across the director compensation table rows.
- Forte Biosciences, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Forte Biosciences, Inc.'s own proxy. As printed: 7,358,587. View filing ↗